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Biphenotypic (hepatobiliary) primary liver
carcinomas: the work in progress
Elizabeth M Brunt1, Valerie Paradis2, Christine Sempoux3 & Neil D Theise*,4
Practice points
●●

Diversity is increasingly recognized in primary liver carcinomas (PLCs), changing
the dichotomy of hepatocellular carcinoma (HCC) and cholangiocarcinoma (CC) as
distinctly separate tumors in all situations.

●●

PLCs with mixed hepatobiliary differentiation have been described in the
literature for over 100 years, first by histopathology, then with the addition of
immunohistochemistry to identify markers of biliary and/or progenitor cell or stem
cell differentiation. The presence of such markers is commonly associated with a
worse prognosis.

●●

PLCs may have mixed ‘hepatobiliary’ features (i.e., biphenotypic [hepatobiliary] PLC)
at many levels: at the gross tissue level, at the microscopic (cellular) morphologic
level or by immunophenotypes. The latter group includes the ‘pure’ HCC with
biliary findings by immunophenotype, pure CC with hepatocytic findings by
immunophenotype, cholangiolocellular carcinomas and PLC without typical
morphology but with mixed hepatobiliary immunophenotype.

●●

Classification of biphenotypic (hepatobiliary) PLC must always begin with the
light microscopic morphologic assessments; immunophenotyping is reserved as a
secondary means of identification.

●●

Molecular studies to date of microdissected biphenotypic (hepatobiliary)
PLCs have shown surprisingly more homogeneity than the histologic and/or
immunohistochemical phenotypes, and are closer to CC than to HCC.

●●

Many clinical, pathologic and molecular questions remain unanswered regarding
these complex tumors; the first task to promote studies that can answer these
questions is to establish consistent consensus terminology and method(s) for analysis.

Recent WHO classification for combined hepatocellular–cholangiocarcinoma and recognized
stem cell subtypes has increased attention to such tumors; however, the resulting burst of
reporting and research indicates that this classification, while provocative, is incomplete for
description of the full array of primary liver carcinomas with biphenotypic (hepatobiliary)
differentiation. We review the history of such lesions and consider the wider array of such
tumors previously described. Mixed hepatobiliary phenotypes and immunophenotypes
are found in individual tumors at the tissue level – with architectural and cytologic features
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supportive of both differentiation states – and at the cellular level, with individual cells that
display cytology of one cell type, but immunophenotypically showing mixed expression.
Pathobiologic and clinical questions to be answered by future research are suggested.
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• cholangiolocellular
carcinoma • combined
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Traditional teaching has it that there are two
interconnected, but separate epithelial compartments in the liver: hepatocytes and cholangiocytes. Traditional teaching follows then that
primary liver carcinomas (PLCs) reflect this
dichotomy: hepatocellular carcinoma (HCC),
and cholangiocarcinoma (CC), each with variants. We now know that hepatobiliary lineages
are more flexible as displayed most prominently
by ductular reactions that are present in liver
injury of all forms in varying degrees. Just as
these reactive lesions display a range of epithelial
phenotypes between the hepatocytic and cholangiocytic differentiation, likewise, increasingly,
similar diversity is being recognized in PLCs.
The other relatively uncommon kinds of primary liver cancers (e.g., mucinous cystic neoplasms, biliary intraductal papillary neoplasms)
and special types of HCC (e.g., fibrolamellar
carcinoma) have established diagnostic criteria that are readily applied. However, increasingly commonly, new forms of PLC are being
seen worldwide: tumors of mixed hepatobiliary
phenotypes and immunoexpression that are
presenting with a wide range of clinical, imaging and histopathologic complexities and, thus
confusion. These include not only the most welldescribed ‘combined hepatocellular–cholangiocarcinoma’ (cHCC-CC), but also several variants
– including those with ‘stem cell features.’
In this review, we discuss and show examples of PLC with such mixed hepatobiliary
features and explore many of the clinicopathologic questions they raise. Some of these tumors
may indeed be new forms of PLC, related to
the changing incidences of important, premalignant conditions; they may be a reflection of
newly recognized PLC variants either because
of detailed hepatobiliary immunophenotyping
not previously available to pathologists or the
newly sensitive imaging techniques in practice
today. Though there are few absolute answers
for the questions that recognition of these
tumors raise, we take this opportunity to put
the discussion first into historical context, then
to detail currently published diagnostic categories, to summarize existing molecular data
concerning the lesions and finally to point to
diagnostic approaches needed to further refine
our understanding of these tumors.
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A final note concerns terminology: there is
currently no accepted consensus terminology for
these tumors. Indeed, expert liver pathologists in
the field are not in full agreement. Some favor
the broad term ‘biphenotypic PLC’; others argue
that this may be imprecise, since there may be
many different forms of biphenotypia outside
the theme of this paper (e.g., HCC squamous,
adenosquamous, sarcomatoid HCC). On the
other hand ‘mixed hepatobiliary carcinomas’ is
preferred by some. The argument against this
term is the implication of specific differentiation
when in fact, some of these tumors may appear
to be monomorphic by light microscopy, and
only the application of immunohistochemistry
(IHC) highlights the true biphenotypic expression of the cells within the tumor. For this
review, we chose to observe the inelegant, albeit
unsimplified convention of this paper’s title:
biphenotypic (hepatobiliary) PLC, abbreviated
to b(HB)-PLC.
An established nomenclature – that is scientifically valid and clinically meaningful – still
needs time to undergo community wide discussion, consensus building, understanding
of pathophysiology and acceptance over the
coming years.
Historical overview
During the last three decades, many publications, partly reviewed in Table 1, have reported
and analyzed liver tumors that are clearly to be
considered b(HB)-PLC. The presence of tumors
displaying features of both hepatocellular and
biliary origin was described for the first time by
HG Wells more than 100 years ago [1] although
Allen and Lisa’s description of five cases is often
cited as the first [2] . In their series, the tumors
were noted as separate or contiguous tumors
with differentiation typical for HCC and CC.
Further description showed two separate tumors
arising distantly in the same liver, two contiguous tumors intermingling at their borders and
one single mass showing both hepatocellular
and biliary features. In the milestone paper of
Edmondson and Steiner published in 1954 [3] ,
4% of their entire series of PLC showed both
hepatocellular and biliary differentiation. Their
recommendation for terminology was ‘hepatobiliary cancers,’ but also recommended that they
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Table 1. Literature review on biphenotypic (hepatobiliary) primary liver carcinomas.
Study (year), (n, if given)

Proposed nomenclature

New concept proposed

Wells (1903), (n = 1)
Allen and Lisa (1949), (n = 5)

Primary carcinoma of the liver
Combined liver cell and bile duct
carcinoma

Steiner et al. (1959), (n = 11)
Goodman et al. (1985),
(n = 24)

Cholangiolocarcinoma
Combined HCC–CC

Maeda et al. (1995), (n = 36)

Combined HCC-CC

First description
Three types:
●● Two distinct tumors in different parts of liver
●● Two separate tumors adjacent and intermingling
●● One tumor with intimately associated cellular components due
to origin from same focus
First description
Three types:
●● Collision: separate HCC and CC in same liver
●● Transitional: single tumor with features of both HCC and CC
●● Fibrolamellar: primarily FL-HCC but with mucin-producing foci
First survival rates after resection: combined HCC-CC has worse
outcomes
Marked difference in survival: shorter if biliary features;
expression of K14 means either derived from progenitor cells or
regressed to the bipotential progenitor cell phenotype during
carcinogenesis
Possibly derived from progenitor cell; by light and electron
microscopy, expression of hepatocyte and biliary keratins
All had ‘transitional’ areas; utilized albumin ISH to prove HC
differentiation; 96% showed both ISH and biliary keratins =
‘biphenotypic’ differentiation
Tumors contained undifferentiated cells with morphological and
immunohistochemical features of hepatic progenitor cells
More similar to HCC, than to CC clinically except more advanced
disease stage; survival worse than HCC and CC
Morphologically intermediate can arise from progenitor cells

Wu et al. (1996), (n = 290
HCC with dual (hepatocellular/
HCC); Wu et al. (1999), (n = 64 biliary) phenotype
from the previous series)
Robrechts et al. (1998), (n=1)
Tickoo et al. (2002), (n = 27)

Intermediate cell tumor; dense
stroma
Combined HCC-CC

Theise et al. (2003), (n = 4)

Combined HCC-CC

Yano et al. (2003), (n = 26)

Combined HCC-CC

Kim et al. (2004), (n = 54)

Primary hepatic carcinoma
of intermediate (hepatocytecholangiocyte) phenotype
HCC only: impact of stemness
features

Kim et al. (2011)

Cazals-Hatem et al. (2004),
Combined HCC-CC
(n = 9)
Durnez et al. (2006), (n = 109) HCC only: impact of progenitor
cell component
Aishima et al. (2006), (n = 40) Combined HCC-CC
Aishima et al. (2007), (n = 35)

Combined HCC-CC

Komuta et al. (2008), (n = 30)

Cholangiolocellular carcinoma

WHO (2010)

Combined HCC-CC

Ref.
[1]
[2]

[4]
[5]

[6]
[7,8]

[9]
[10]

[11]
[12]
[13,14]

K19 correlated with clinicopathologic features of tumor
aggressiveness, more invasive characteristics, compared with
K19-negative HCCs through the upregulation of EMT-associated
genes
Closer in mutations to CC than to HCC

[15]

>5% K19 positivity = higher recurrence rate and worse prognosis

[16]

Four subtypes based on the amount of CC component: outcomes
relies on ≥60% CC component and/or sarcomatous component
HCC smaller than 3 cm in diameter can have biliary differentiation
and prognosis is worse
Investigated relationship to HPCs, HCC and CC: CLC and K19 HCC
have high homology: both are likely progenitor cell derived
association with HCC and sometimes with CC
Unequivocal components of both HCC and CC in same
tumor; does not include two separate tumors either in same
liver or simply adjacent to each other; four types: classic or
stem cell features (three subtypes: typical, intermediate and
cholangiocellular)

[17,18]

[19]

[20]

?: Questioned if tumor was of progenitor cell origin; CC: Cholangiocarcinoma; CLC: Cholangiolocellular carcinoma; HCC: Hepatocellular carcinoma;
HCC-CC: Hepatocellular–cholangiocarcinoma; HPC: Hepatic progenitor cell; IHC: Immunohistochemistry; ISH: In situ hybridization; PLC: Primary liver carcinoma.
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Table 1. Literature review on biphenotypic (hepatobiliary) primary liver carcinomas (cont.).
Study (year), (n, if given)

Proposed nomenclature

Roncalli et al. (2010)

Three types:
All are subtypes of ‘progressed HCC’
●● HCC with stem/progenitor cell ●● >5% of tumor cells express stem/progenitor IHC markers: K19,
EpCAM, CD133, etc.; not recognizable by H/E
immunophenotype
? origin from progenitor/stem cell or dedifferentiation
●● Mixed hepatobiliary, classical
from mature hepatocytes; increased likelihood recurrence,
type
resistance to treatment, mets
●● Mixed hepatobiliary with stem/
●● Uncommon; combined HCC-ChC; can be detected by HE and
progenitory phenotype and
confirmed with IHC:HC component by HepPar, pCEA, CD10;
immunophenotype
ChC by K7, K19; mucin for mature biliary component; may
have intermediate components at interface: K7, 19, CD56, c-kit,
EpCAM (derivation from stem/progenitor; px is poorer than
usual progressed HCC
●● Rare; majority of tumor is stem/progenitor or intermediate;
other names: hepatic stem cell; PLC of intermediate phenotype;
cholangiolocellular [14,22–25]; Laennec society proposed
name: mixed hepatobiliary carcinoma with stem/progenitor
cell features
Px uncertain due to small numbers
Large-sized CLC had high recurrence
Intermediate ca survival was intermed b/w HCC and CCa
HCC, CC and combined HCC-CC
By gene expression studies, distinct tumors but some HCC close
to CC
Combined HCC-CC
Added DLK-1 to IHC panel; separated cases into groups A and B
according to < or >5% stem cells cases with >5% stem cells had
worse prognosis; DLK-1 was usually pos in those cases
Combined HCC-CC
To confirm the classification of four subtypes of WHO, no effect of
this classification

Woo et al. (2010)
Ikeda et al. (2013), (n = 36)

Akiba et al. (2013), (n = 54)

New concept proposed

Ref.
[21]

[22]
[26]

[27]

?: Questioned if tumor was of progenitor cell origin; CC: Cholangiocarcinoma; CLC: Cholangiolocellular carcinoma; HCC: Hepatocellular carcinoma;
HCC-CC: Hepatocellular–cholangiocarcinoma; HPC: Hepatic progenitor cell; IHC: Immunohistochemistry; ISH: In situ hybridization; PLC: Primary liver carcinoma.

be contained within the group of HCC as they
were mostly observed in men on a cirrhotic background, as with classical HCC. This combined
type of cancer was considered by the authors
as ‘a problem difficult to solve at the present’, a
relevant opinion today, 60 years later.
The first part of the 20th century was the era
of histopathology alone and extensive descriptions of the histological and cytological characteristics of b(HB)-PLC were supported by
numerous photomicrographic figures. Since
that time, a diagnosis of b(HB)-PLC requires
the unequivocal histological presence of both
hepatocellular and cholangiocellular elements
within the same tumor, as stated by the 2000
WHO classification of the digestive tumors [28] .
With the developments of IHC new concepts emerged. In 1985, Goodman [5] reported
the experience of the Armed Forces Institute of
Pathology with 24 cases and classified them in
three categories, only slightly modified from
those of Allen and Lisa. The first was termed
the ‘collision type,’ corresponding to the
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coincidental occurrence of both HCC and CC,
distinctly separate, in the same liver. The second
was the ‘transitional type,’ with intermediate
differentiation and areas of transition between
HCC and CC. The third was the ‘fibrolamellar type,’ resembling fibrolamellar HCC, but
containing pseudoglands producing mucin.
α-fetoprotein, a marker of hepatocytic differentiation, and staining for ‘keratins’ (polyclonal
antikeratin antibodies unspecified in the study,
but probably against those typically expressed
in cholangiocytes alone, such as K7 and K19),
markers of cholangiocytic differentiation, were
both found to be expressed in these mixed
tumors collectively termed ‘combined hepatocellular cholangiocarcinomas’ according to the
authors.
IHC was subsequently used more and more
in order not only to help in diagnosing PLCs
of all kinds and to distinguish between them
and poorly differentiated metastatic carcinomas, but also to assess their origin(s), and to
study and subtype HCC and, to a lesser extent,
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CC [6–7,29–37] to yield prognostic information.
It has since been shown that approximately
25–30% of HCC diagnosed by histology show
an expression of biliary markers, such as K7
and/or K19 and this has been correlated to a
worse prognosis [7,13,16–18,38] . Furthermore, in a
study from 2002, Tickoo et al. investigated 27
mixed tumors with IHC for biliary markers and
with in situ hybridization for albumin mRNA,
a specific marker for hepatocyte differentiation [10] . A positive albumin signal was found in
96% of PLCs and the authors concluded in favor
of a biphenotypic differentiation.
Because of these results and the developing
evidence for the existence of human hepatobiliary stem cells during the same era [39–42] ,
the idea of a stem/progenitor cell origin for
b(HB)-PLC gained increasing traction. The
first direct evidence of this possibility was in
a collection of four cases of cHCC-CC ‘with
stem cell features.’ [11] . In all four cases, there
were populations of small cells, with high
nuclear:cytoplasmic ratio, dense nuclear chromatin, arrayed around nests of hepatocytic
and/or cholangiocytic cells. In all of these cases
cells of intermediate morphology lay between
these stem cell-like components and the more
differentiated components, suggesting a visible
maturation lineage.
Furthermore, different authors using different
immunomarkers such as K19, K14 (cluster of
differentiation) CD117/c-kit or EpCAM (epithelial cell adhesion molecule) identified progenitor cell expression in b(HB)-PLC and/or in
otherwise typical HCC [8,13–14,16,23–24,36] . It was
postulated that HCC in which a subpopulation

Review

is found expressing K19 arise from progenitor cells [16,25] or result from dedifferentiation
or transdifferentiation of tumoral hepatocytes
yielding expression of ‘stemness’ features. This
characteristic has always been associated with a
worse prognosis [13,22] .
Studies in the past decade undertaken to
search for a relationship between b(HB)-PLC
and classical CC or HCC have shown contradictory results, probably related to the differing
terminology as well as diagnostic criteria used
by the different investigators [12,15,22,43–44] .
Moreover, the spectrum of b(HB)-PLC was
expanded with reports of new histological features, associated with progenitor cell IHC markers. An example is the most recently proposed
tumor. In 2001, Shiota et al., [45] reported a series
of cholangiolocellular carcinoma (CLC), a particular type of PLC that had been described initially by Steiner in 1959 [4] , but only by routine
histochemical evaluation. CLC are usually [19] ,
but not always [46] associated with HCC in continuity or elsewhere within the liver. These may
or may not also contain overt CC. The characteristic histologic feature is anastomosing regular ductules without lumina resembling canals
of Hering in a dense, sclerotic stroma in which
the epithelial component resembles the benign
counterpart, that is, the ductular reaction [33] . In
fact, this appearance itself led Shiota et al. [45] to
consider a possible stem cell origin for the tumor.
Detailed studies by Komuta et al. in a study of
30 cases of CLC by morphology (both light
and electron microscopy), IHC and molecular
biology strongly support a stem/progenitor cell
origin for CLC [19] .

Table 2. Descriptive versus WHO classification of primary (mixed hepatobiliary) liver
carcinomas.
Descriptive classification

2010 WHO classification

Stem cell/biliary marker positive (particularly K19+)
‘pure’ HCC
HCC, small cell subtype
HCC with stem cell features and IHC markers
Hepatocyte marker positive pure CC
cHCC-CC
cHCC-CC with ‘typical’ stem cell features
cHCC-CC with ‘intermediate’ features
Cholangiolocellular carcinomas with HCC
component
Cholangiolocellular carcinomas with cHCC-CC
Primary liver carcinoma with mixed hepatobiliary
IHC features (non-HCC, non-CC)

HCC
HCC
Unclassified
Unclassified
cHCC-CC
cHCC-CC, typical stem cell subtype
cHCC-CC, intermediate stem cell subtype
Unclassified
cHCC-CC, cholangiolocellular subtype
Unclassified

CC: Cholangiocarcinoma; cHCC-CC: Combined hepatocellular–cholangiocarcinoma; IHC: Immunohistochemistry.
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As a consequence of such IHC studies, criteria to accurately diagnose b(HB)-PLC became
confused. Are morphologically pure HCC or
CC that display immunophenotypes of either
stem, progenitor or mature epithelial cells of the
‘other’ cell type actually a different tumor class?
Or are they merely a subclass of the pure tumors
with different prognostic markers (similar to the
prognostic markers in clinical breast oncology)?
Do overt histologic ‘stem cell features’ have clinical significance that warrants a separate diagnostic category? Furthermore, if stem cell features
are only apparent by immunostains, should
these be considered ‘stem cell tumors’? These
and other important questions that arise from
them are undergoing investigation, but currently
there are no consensus answers.
The clinical impact of these reports led to
a revision of the classification of such tumors
by the WHO in the 2010 publication [20] . In
this publication, for the first time, there is an
entirely separate chapter to explore b(HB)-PLC
(therein referred to as ‘combined hepatocellular–
cholangiocarcinoma’). This redefinition is preliminary, inherently reflecting our early, incomplete understanding and describes two different
forms: the classical cHCC-CC containing histologically typical areas of HCC together with
those of CC within the same tumor; and the
cHCC-CC with stem cell features. In the WHO
2010 chapter, this latter subtype is further
divided into three categories: typical (nests of
mature hepatocyte-like tumor cells surrounded
by small cells exhibiting IHC markers of progenitor cells), intermediate (small homogeneous tumor cells comprising most of the tumor
that are intermediate between hepatocytes and
cholangiocytes and showing IHC markers of
both) and CLC [20] . In all of these groups, the
histologic assessment is diagnostic, with IHC
playing only a supportive, confirmatory role in
tumor classification.
The revised WHO classification was utilized
recently by Akiba et al. [27] in a study of 54 cases;
the authors underlined the complexity of the
histological features in b(HB)-PLC named and
classified according to the 2010 WHO guidelines (i.e., cHCC-CC with or without stem
cell features) and the difficulties in its application, as only 1 of the 54 cases fit criteria of
‘typical.’ The difficulty was also emphasized by
the study of Ikeda et al. [26] who recommended
evaluating the amount of stem cell features (as
a percentage) in order to predict the prognosis.
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Sasaki et al. [47] also highlighted the variability of
stem cell features in any given b(HB)-PLC, but
also pointed out that different ‘stem cell feature’
subtypes were often present in the same tumor
and, moreover, could be identified in many classical HCC with careful attention. Significant
clinicopathologic associations were found with
the presence of stem cell features [47] .
b(HB)-PLC are frequent in cases of preexisting liver disease, especially HCV and advanced
fibrosis [33,48] . These tumors have also been
reported in persistent or recurrent tumors after
transarterial chemoembolization. This outcome
of treatment in some cases may potentially
impact the prognosis of patients after liver transplantation [49,50] and raises again the question
of transdifferentiation versus stem/progenitor
cell origin. However, in clinical practice, these
tumors are being noted with increasing frequency in nondiseased liver as well [EM Brunt,
Unpublished Data] .
Importantly, new, cutting edge work by
Holczbauer et al. [51] confirms that human
HCC cell lines showing hepatocytic features can
change genetic programming to become cancer
stem cells with bipotent hepatobiliary differentiative potential. As Zucmann-Rossi and Nault
pointed out in an accompanying editorial [52] ,
this work confirms that PLC may variously
derive from malignant transformation of adult
hepatocytes, liver stem/progenitor cells and fetal
hepatoblasts, all of which can give rise to the
mature-appearing cells of these tumors as well
as to cancer stem cells within them that sustain
tumor self-renewal and resistance to treatment.
Raggi et al. [53] have further established that
DNA methylation is a key epigenetic regulatory
mechanism determining the pool of PLC cancer
stem cells.
Histologic & immunophenotypic diversity
of b(HB)-PLC
Leaving aside variations of straightforward
‘pure’ (i.e., typical) HCC and pure CC, which
are not reviewed, we summarize the histologic
and immunophenotypic features of the various
forms of b(HB)-PLC reported to date (Table 2) .
Two ‘broad’ groups of tumors show a mixture of
biphenotypic (mixed hepatobiliary) phenotypes
expressed at either the tissue or cellular levels.
●● Tumors with biphenotypic/mixed hepatobil-

iary features at the tissue level show co-mingling of malignancies of the two different
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cytologic and architectural features of HCC
and CC, sometimes with cells of intermediate
cytology/immunophenotype between them.
These are commonly recognizable by light
microscopy.
●● Tumors with biphenotypic/mixed hepatobil-

iary features at the cellular level are not often
recognized as such by light microscopy. These
are largely monomorphic, and may be of varying differentiation with or without a stromal
component. However, with use of IHC, these
tumors display mixed immunophenotypes
either focally or diffusely within the tumor.
These may be ‘traditional’ HCC or CC with
immunostaining for markers of the other cell
type or monomorphic tumors that cannot be
classified histologically as either type, but in
which immunophenotypic evidence is demonstrated for combined hepatobiliary features
at the cellular level.

Figure 1 is a schema to organize our knowledge
of PLC. The areas denoted within each segment
are not intended to reflect prevalence or incidence of each type within the clinical spectrum
of PLC, although obviously straightforward
HCC and CC are the most common. The schematic is meant as a device for organizing our
knowledge of these tumors and as a stepping
stone toward development of a robust, clinically
relevant nomenclature.
Immunomarkers that are commonly used
or that have been used in research efforts will
also be discussed in each section. A variety of
hepatocyte markers, cholangiocyte markers
and stem cell markers are recognized, some of
which are common in many clinical laboratories, others of which are uncommon outside of
research settings. These are collectively highlighted in Table 3. It is gratefully acknowledged
that that this table was generated through

Bi-phenotypic
(hepatobiliary)

HCC

Review

CC

PLC
Morph’l
HCC

Morph’l
HCC
with
Biliary
IHC

including

Morph’l
CC
with
Hepatocytic
IHC

Morph’l
CC

Combined
HCC-CC

Pure HCC
with SCF

Combined
HCC-CC
with SCF

Pure CC
with SCF

Monomorphic
tumors
with mixed
hepatobiliary IHS

Figure 1. Schematic diagram representing our present interpretation of primary liver carcinoma.
The areas assigned to each segment area are not reflective of prevalence or incidence of each type.
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Table 3. Immunohistochemical markers for evaluating differentiation in biphenotypic (hepatobiliary) primary liver carcinoma.
Hepatocyte differentiation

Biliary
differentiation

Stem cell differentiation
Stem cell differentiation
with stem cell morphology without stem cell
morphology

Common markers
(use as panel or use in
sequence until a positive
result is obtained)

HepPar1, Arginase-1,
canalicular staining with
CD10, canalicular staining
with pCEA, AFP

Keratin 19, NCAM (CD56),
EpCAM, EMA (Muc-1), c-kit
(CD117)

No available common
markers

Experimental markers
(supplemental to
‘common markers’)

Nuclear staining for HNF4a

Keratin 7, Keratin
19, cytoplasmic
staining for CEA
(pCEA or mCEA),
EMA (Muc-1)
Nuclear staining for
Sox-9

Nestin, Keratin 14, CD133,
nuclear staining for Sox-9

Nuclear staining for Oct-4
Nuclear staining for Nanog
Nuclear staining for Sall-4

Bold text highlights the antibodies to be used.
For each differentiation state within a b(HB)-PLC – hepatocellular, biliary and stem cell – several markers are available; however, availability or cost may limit the utility of such large
panels. On the other hand, lack of consistency between studies and/or centers can result in data that cannot be easily compared between different studies. To limit these
difficulties, the panels in the upper row are recommended to be used either: as a panel with all antibodies applied to every case; or in a sequence, top to bottom, stopping with
the first positive antibody. The markers in the bottom row are recognized as having utility for studying b(HB)-PLC, but are considered supplemental to the primary panels listed
first. It is emphasized that morphology is primary in the assessment of subpopulations and immunophenotyping is secondary. In particular, stem cell components are assessed
by routine light (H&E) microscopy before confirming by immunohistochemistry.

group discussion and with approval from the
members of the 2013 meeting of the Laennec
Hepatopathology Society held in Singapore
(Aileen Wee, MD, USA host).
●●Pure HCC with biliary (stem cell)

immunophenotype
Hepatocyte-like tumor with stem cell
immunophenotype

Keratin 19 positive HCC is defined as a tumor
with purely typical features of hepatocellular differentiation and which expresses keratin 19 in
≥5% of its cells; these cells are usually or mostly
hepatocyte-like in morphology (Figure 2A & B) .
Such tumors (with the arbitrarily selected 5% cut
off) have been shown to have a poorer prognosis
with diminished disease free survival, increased
likelihood of metastasis, greater chemoresistance and diminished life expectancy [16,54] .
Some have argued that this indicates that it
should be treated as a separate, distinct subclass
of HCC [36] ; however, one can also argue that it
should merely be considered a prognostic indicator. The latter position is supported by the
apparent emergence of keratin 19 expression or
even overt cHCC-CC in recurrent HCC that
previously had undergone ablative therapy [55] .
Thus, rather than a distinct type of b(HB)-PLC,
K19-positive HCC may perhaps better be considered in the spectrum of HCC itself. Future
prospective clinical studies may be of value in
further addressing these questions, keeping in
mind that of the biliary markers K19 may also
correlate with other marker expression of biliary and/or stemness antigens such as CD56,
EpCAM and CD133.
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Isolated tumor cells with stem cell
morphology confirmed by stem cell
immunophenotype

Among the predominant hepatocyte-like cells
in a pure HCC, are small, round to cuboidal,
cells phenotypically similar to those of the
canal of Hering in normal livers. Such stem
cell-like tumor cells may be recognized by
immunostaining for K19, CD56, EpCAM,
CD133 and/or CD117/c-kit (at least). They are
scattered individually or in clusters within the
tumor (Figure 2C & D) or they may distribute along
stromal boundaries either at the edges of the
HCC or, more frequently along fibrous bands,
within the tumor (Figure 2E & F) [11,55–56] . While
the marker immunostaining is usually sharply
defined and limited to these smaller cells, morphology may reveal a pattern of cellular changes
suggestive of a maturation lineage: from small,
marker-positive, stem cell morphology to overt,
marker-negative hepatocyte morphology. The
frequent juxtaposition of the small cells against
stroma is tempting to consider as a malignant
variant of an hepatobiliary stem cell niche, complete with cell:matrix localization that would
potentiate interactions. The clinical implications
of these stem cell-like findings, however, remain
uncertain.
●●Pure CC with hepatocytic

immunophenotype

The presence of some form of hepatocytic markers in CC has not been well studied. Hepatocyte
in paraffin-1 (HepPar1) and arginase-1 have
both been reported to be expressed in a minority of CC that are otherwise devoid of hepatocyte
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morphology [57,58] . There are no reports to suggest that such hepatocytic expression indicates
CC with better prognosis; clearly these are otherwise typical CC in terms of their biology. It is
also uncertain whether this should be taken as
evidence of stem cell origin of some CC or redifferentiation reflecting the flexible gene expression of non-neoplastic hepatobiliary lineages. It
is worth noting, after all, that one may sometimes observe hepatocytes within non-neoplastic
bile ducts.
●●cHCC-CC

By initial H&E evaluation, these tumors will
show two intermixed cytologic/architectural
patterns (Figures 3–5) : areas suggestive of CC,
for example, gland formation or strands of small
cells with little cytoplasm or angulated ‘glands’
with poorly formed lumina, all of which usually
occur in dense acellular stroma, and of HCC,
that is, variably pleomorphic hepatocyte-like
cells often with growth showing distortions
of normal liver parenchyma, such as thickened trabeculae or massively dilated canaliculi
(‘pseudoglands’ or ‘pseudoacini’). The HCC
component may have any of the common findings in pure HCC, such as steatosis, ballooning
with Mallory-Denk bodies and intercellular or
intracellular bile accumulation.
Where the CC and HCC components meet
the change may be abrupt or there may be transitional cytologic, immunophenotypic or architectural features. For example, there may be pseudoacinar formations lined not by hepatocytes,
but by cuboidal, cholangiocyte-like cells, there
may be what appear to be malignant variations
of ductular reactions in which immunophenotyping demonstrates a lineage-like range
of cytology and immunophenotypes ranging
between cholangiocyte-like and hepatocytelike. These transitional areas may include not
only the epithelial portions of the tumor, but
also the amount and nature of the stroma; dense
hyaline stroma readily characterizes many types
of cholangio/cholangiolo/stem/progenitor cell
carcinomas, These areas of dense hyalinized
stroma may also include central areas of nearly
‘empty’ stroma in which epithelial components
are absent and only ghost-like spaces reminiscent
of the structures remain.
By convention, fibrolamellar carcinoma is not
considered such a tumor even though phenotypic
markers that could be utilized to argue in favor
of b(HB)-PLC and a unique ‘lamellar’ fibrous
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Figure 2. ‘Pure’ hepatocellular carcinoma with
biliary (stem cell) immunophenotype.
(A & B) Hepatocyte-like tumor cells with stem
cell immunophenotype: the features are those
of hepatocellular differentiation with keratin 19
expressed in ≥5% of the cells (in this case, 80%;
hematoxylin and eosin [H&E] and K19, 15-times).
(C & D) Hepatocyte-like tumor cells containing
isolated tumor cells with stem cell morphology
confirmed by stem cell immunophenotype, in
this case, K19 (expressed in 5%; H&E and K19,
10-times). (E & F) Hepatocyte-like tumor cells
comprise the majority of the tumor, but tumor
cells with stem cell morphology can be seen
at (E) the stromal interface or (F) within the
hepatocellular carcinoma (H&E, 10-times and
15-times, respectively).
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individuals and without association with chronic
liver diseases) nor its clinical outcomes are similar
to b(HB)-PLC being discussed herein. Likewise,
the still rarer variant of scirrhous HCC, despite
similar mixed immunophenotypes, is not
included in this category [58] .
●●cHCC-CC with stem cell features

A

B

C

Figure 3. Biphenotypic (hepatobiliary) primary
liver carcinoma. Immunohistochemistry
highlights the mixed hepatobiliary nature
of the tumor. (A) By hematoxylin and eosin
stain, the tumor has an appearance of a
monomorphic tumor both architecturally
with cords and nests of tumor cells in a dense
stroma, and cytologically with very little tumor
cell pleomorphism (hematoxylin and eosin,
15-times). (B) Immunohistochemical detection of
HepPar-1 in scattered tumor cells highlights foci
of tumor cells with hepatocyte differentiation
(10-times). (C) Immunohistochemical detection
of K19, a biliary or stem cell marker, is noted
diffusely and uniformly strongly throughout the
tumor (10-times).

stroma are present [59] . It is excluded from consideration in this group of tumors because neither
the clinical presentation (typically in younger
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This is a heterogeneous group of tumors that have
been included in the current WHO tumor classification; however, that classification is imperfect
in many respects, though it has served to raise
interest in and stimulate research about these
lesions and others described in this paper. Those
with the most overtly stem cell-like features
were the first ones described [11] , and were thus
designated ‘typical’ in the WHO classification,
though subsequent series make it clear that these
are uncommon at best [26–27,47] . What makes
them so evocative is the presence of small stem
cell-like cells that are contiguous with regions of
HCC and with regions of CC, but also surrounding islands of well-differentiated hepatocytes
without significant cytologic atypia, simulating
a ductular reaction surrounding a cirrhotic nodule, as though these presumably neoplastic cells
are capable of giving rise to ‘normal’ hepatocytes.
The striking appearance of these areas even without any immunohistochemical staining is what
drew attention to the lesions in the first place [11] .
Additionally, there are cHCC-CC in which
the majority of tumor cells show ‘intermediate’
morphology or what may appear to be ‘small
hepatocytes’ [14] . The pattern may include trabeculae or elongated, ill-defined gland-like structures in dense stroma, but true gland formation
with well-defined lumens and mucin production
are absent. These cells stain for a combination of
hepatocyte and cholangiocyte makers, and often
for CD117/c-kit (Figure 6) .
Though the current WHO classification
includes this group of historically well-recognized tumors as a stem cell subtype of cHCCCC, its relative frequency compared with those
other types and its longstanding recognition as
a separate category of tumor perhaps still merits
it being separated as a distinct subtype. When
the cholangiolocellular component predominates in the tumor, rather than as appearing as
a small subtype within a larger, different tumor
mass, this designation is warranted. Many of
these, though not all, will have either a clear
HCC component or a clear CC component or
both [19,46] . These recent data indicate, therefore,
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Figure 4. Biphenotypic (hepatobiliary) primary liver carcinoma. (A) By routine hematoxylin and
eosin staining, it is apparent there are morphologic features of both hepatocellular carcinoma
and cholangiocarcinoma in this tumor. The former is appreciated by trabeculae, and the latter by
glands (hematoxylin and eosin 15-times). (B) Immunohistochemical reactivity of the glandular
components is strong with K19; this stain also highlights the negative reactivity of much of the
tumor (15-times). (C) Immunohistochemical detection of pCEA is in the canalicular components of
the hepatocellular carcinoma, and lining of well-formed glandular components. No cytoplasmic
reactivity is appreciated, as would have been expected in a cholangiocarcinoma (15-times).
(D) Immunohistochemical detection of CD10 is similar to pCEA and is restricted to the canalicular
components of the hepatocellular portions of the carcinoma (15-times).
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Figure 5. Combined hepatocellular–cholangiocarcinoma. (A) By hematoxylin and eosin (H&E),
there is an hepatocellular carcinoma (HCC) area showing hepatocyte-like tumor cells associated
with tumor cells with stem cell morphology (H&E, 100-times). (B) A cholangiocarcinoma (CC) area
shows cuboidal cells arranged in gland formation associated with an acellular fibrous stroma
(H&E, 100-times). (C) This photomicrograph shows a transitional area with closely approximated,
small homogeneous tumor cells intermediate between hepatocytes and cholangiocytes (H&E,
100-times). (D) Immunohistochemical detection of glypican 3 is reactive in HCC area (200-times).
(E) Immunohistochemical detection of K7 is reactive in CC area (200-times). (F) On macroscopic
examination, this primary liver carcinoma appears relatively monomorphic, with features that are
similar to CC than to HCC. These gross features include the white-tan color, firmness of the tumor and
lack of obvious necrosis or bile.

that not all of these tumors, regardless of the
recent WHO classification, are in fact cHCCCC. It is felt that the dominant, cholangiolocellular compartment recapitulates features of the
normative canal of Hering/ductule and perhaps
the name should be limited to those tumors in
which this compartment is well differentiated
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with minimal pleomorphism; cases in which
higher grade, pleomorphic variants mimic this
pattern are perhaps not the same entity. This
bland tumor can be a ‘mimic’ of ductular reaction [33] in cirrhotic septum on a small biopsy,
but without the expected inflammation and
vascular spaces of shunting present in the latter.
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●●PLC without typical morphology but with

mixed hepatobiliary immunophenotype

These apparently novel PLCs which fit neither
into the general categories of HCC, CC or cHCCCC have most dramatically made the case that a
tripartite division of hepatobiliary malignancy is
insufficient. These are tumors whose histomorphology differs from these three well-established
PLCs, whose immunophenotypes often show
considerable diversity both with heterogeneous
staining for different hepatobiliary markers, but
also including, occasionally, nonhepatobiliary
antigens, for example, those associated with squamous or endocrine or sarcomatous differentiation.
Behavior of these tumors is not certain given that
they are not in fact a uniform class, though the
significant biliary features (either as overt CC,
IHC expression of biliary/stemness markers or in

Review

behaviors such as perineural and lymphatic invasion) suggest that their behavior will be likely
more akin to CC than to HCC.
An example of such a tumor is shown in
Figure 7. This figure should not be taken to be a
new and specific tumor type; it is just one example of a quite heterogeneous group of previously
poorly recognized or described b(HB)-PLC.
Indeed, whether these represent a ‘new’ kind of
PLC or have been present, but only now being
recognized, due new emphasis on stem/progenitor cell interplay in hepatic neoplasia and more
extensive immunostaining available globally,
remains to be determined.
Molecular aspects of b(HB)-PLC
In recent years, molecular approaches dedicated
to human liver neoplasms have provided in depth

A

C

B

D

Figure 6. Cholangiolocellular carcinoma. (A) This is a needle biopsy that illustrates the
bland nature of the proliferative tumor cells in cholangiolocellular carcinoma. The tumor has
the low power appearance of ductular reaction in cirrhotic septa, but the typical vascular
proliferation and inflammation of septa are notably absent (hematoxylin and eosin four-times).
(B) Immunohistochemical detection of HepPar1 shows occasional positivity in this small area of
the tumor (20-times). (C) Immunohistochemical detection of K7 highlights the diffuse positivity
of this marker of mature biliary cells and also shows the anastomosing nature of the tumor
tubules (10-times). (D) Immunohistochemical detection of CD56 is also diffusely positive; this
marker can be positive in a ductular reaction in certain types of reactive cases, as well as in certain
cholangiolocellular carcinoma (10-times).
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Figure 7. Primary liver carcinoma without typical morphology but with mixed hepatobiliary
immunophenotype. (A & B) Hematoxylin and eosin photomicrographs illustrate small and large
glandular-like formations with tumor cells of little pleomorphism, high N:C, vacuolated nuclei
embedded within varying degrees of stroma (20-times). (C & D) Immunohistochemical detection of
HepPar and CA19-9, respectively, show scattered reactivity, highlighting ‘biphenotypia’ (20-times).
(E & F) Immunohistochemical detection of K19 and EpCam, respectively highlight ‘stem-ness’
(20-times).
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insights into biological behavior and pathogenesis, in both benign and malignant hepatocellular
tumors. Whether morphological heterogeneity, a
critical hallmark of b(HB)-PLC as emphasized
above, reflects molecular heterogeneity has not
been specifically addressed. Molecular studies
focusing on such complex tumors would ideally
include the preliminary step of tumor microdissection, in order to obtain gene expression profiles
according to the different, distinct morphologic
patterns. Nevertheless, based on the few studies of a relative low number of b(HB)-PLC, the
following relevant information is known to date.
●●b(HB)-PLC: a clonal tumor

HCC and CC areas from a series of 11 b(HB)PLC were subjected to laser microdissection
for clonal analysis by studying allelic status of
a number of selected chromosomes’ arms [60] .
Unexpectedly, loss of heterozygosity (LOH) at
multiple chromosomal loci were identified in
all tumors with three different LOH patterns,
including biclonal neoplasms in three cases,
consistent with the previously so-called collision tumors, and single clonal neoplasms in
eight cases, including four with homogeneous
genetic changes and four with genetic divergence. The common allelic losses shared by both
tumor components were strongly suggestive of
a single clonal derivation. Although performed
on a limited number of cases, these clonal data
are critically relevant, highlighting the relative
discordance between morphologic heterogeneity
and molecular homogeneity.
●●Molecular overlap of b(HB)-PLC with

cholangiocarcinoma

There are several studies of chromosomal
changes and gene expression patterns in b(HB)PLC. To note, none have included a preliminary
tumor microdissection step. Thus, a series of 15
b(HB)-PLC (specifically typical cHCC-CC) was
screened for LOH using 400 microsatellite markers, p53 and b-catenin mutations and compared
with three collision tumors, nine CC and a set
of 137 HCC [15] . A high level of chromosome
instability was found in both CC and cHCC-CC
with recurrent specific LOH identified at 3p and
14q, more frequently observed in both CC and
cHCC-CC compared with HCC. According to
these results, the authors suggested that cHCCCC is genetically closer to CC than HCC. This
was further confirmed in a recent study, aiming
to investigate the molecular pathways associated
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with pathogenesis of CLC. To address this issue,
a genome wide transcriptional analysis was performed in a set of 20 CLC [43] . The comparative
analysis with CC and HCC demonstrated that
CLC clustered with CC by hierarchical analysis
while HCC and normal liver samples clustered
together and CLC displayed biliary differentiation
gene signature in parallel with downregulation
of the hepatocyte differentiation program. These
data are consistent with previous immunophenotypical analysis performed in a set of 30 CLC. As
noted above, in this series, all cases had HCC-like
areas, while 63% had CC-like areas. Strong positivity of mature cholangiocytic markers (K7 and
K19) was present in all cases in both cholangiolocellular areas and areas of overt CC, when present, while hepatocellular markers (HepPar1 and
canalicular staining with anti-CD10 and pCEA
antibodies) were positive in HCC-like areas [19] .
●●Molecular pathways involved in b(HB)-PLC

Notably, TGF-b-signaling pathway has shown to
be specifically deregulated in CLC, with a significant number of upregulated fibrosis-associated
genes, including genes encoding profibrogenic
cytokines, extracellular matrix components and
remodeling enzymes [43] . Such molecular features might be expected in CLC which is usually
rich in stroma. Whether a similar extracellular
matrix signature could be a common feature
of other b(HB)-PLC subtypes certainly merits
investigation. Interestingly, increase in TGF-bsignaling pathway expression, including TGF-b,
TGFbR1 and Smad4, has also been reported in
a subset of HCC characterized by the presence
of prominent fibrous stroma, namely ‘scirrhous
HCC’ [61] . In addition, scirrhous HCC displayed
a CC-like gene expression trait that could be
at least partly attributed to the presence of the
tumoral fibrous stroma [61] .
●●Nomenclature & research methodologies

The 2010 WHO designation of cHCC-CC with
and without stem cell features, and the three
subtypes of ‘cHCC-CC with stem cell features,’
has several organizational benefits: defining and
cataloging some of the diversity of b(HB)-PLC,
recognizing that the CLC is likely a progenitor
cell carcinoma with poor clinical behavior and
‘grouping’ of otherwise disparate primary tumors
within the liver by immunophenotype and poor
clinical outcomes. However, the attempted brevity reflected by these subtypes does not, in fact,
encompass all that one encounters either in
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practice or in experimental settings. The previously referenced study by Akiba et al. [27] of
b(HB)-PLC has shown the challenges of utilizing this WHO classification. While the careful
delineation of the subgroups by IHC analysis
documented the rarity of the typical subtype
compared with intermediate and cholangiolocellular subtypes, the categorization led to no significant differences in clinical outcomes between the
groups or subgroups. Furthermore, the authors
noted that while confirmation of progenitor cell
phenotype could be made by their study, the spectra of histology was still not entirely met by the
WHO criteria and more work would be beneficial
to further understand these tumors. The study by
Sasaki et al. [47] further emphasizes these problems by showing that many b(HB)-PLC display
more than one subtype of stem cell features.
Thus, it is clear that for further, efficient development of a rational, clinically useful classification scheme for b(HB)-PLC, a uniform approach
to study would be of benefit. At a recent meeting
of attending members (see Acknowledgements)
of the Laennec Hepatopathology Society 2013
Meeting held in Singapore consensus regarding nomenclature was judged premature, but a
proposed consensus regarding efficient research
standards was achieved. These recommendations
were:
●● Multiple areas of each tumor deserves evalua-

tion in order to be appropriately classified,
based on:
ūū Radiologic evaluation and subsequent careful

radiologic-gross pathologic correlation at the
bench, or
ūū Sampling of grossly different areas of tumor at

the time of gross description or

Conclusion
The identification and analysis of b(HB)-PLC
raise many questions crucial for understanding
minimum diagnostic criteria (clinically, radiologically and pathologically), prognostic assessments, development of appropriate treatments
and monitoring the possibly changing epidemiology of PLC worldwide. These include (but are
not limited to) the following questions:
●● These tumors may be seen with and without
chronic liver disease: are they becoming more
c om mon ? Or were t he y si mply
‘underappreciated’ or ‘underevaluated’ in prior
studies?
●● If they are more common is this due to chang-

begins with morphologic assessment for hepatocyte-like (large cells, arrayed in pseudoglands,
thickened trabeculae or round, tubular structures, surrounded by CD34+ endothelium);
cholangiocyte-like (forming glands, with or
without mucin production) and stem-like
(small cells round, oval or cuboidal cells with
high nuclear:cytoplasmic ratio, hyperchromatic
nuclei).

ing epidemiology of underlying chronic diseases (e.g., the denouement of HCV disease
and, subsequently, increased prevalence and
incidence of malignancy in NAFLD)? Could
the increasingly common setting of post-treatment, but unremitted liver disease be creating
a new tumor environment in which b(HB)PLC are more likely to emerge (e.g., patients
with unsuccessful antiviral regimens)? Is the
increasing prevalence of mixed diseases
(e.g., viral hepatitis and NAFLD, mixed viral
infections) related to b(HB)-PLC development?

●● Immunophenotypic evaluation follows with

●● How much (if at all) do the clinical features and

ūū Laser capture microdissection from slides.
●● Identification of subpopulations within a tumor

standardization of immunohistochemical
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markers for hepatocellular, cholangiocellular
and stem/progenitor cell differentiation
(Table 3) . To promote uniformity of approach
between research laboratories and to foster data
sets that can be easily compared across geographic and institutional boundaries these
antibodies are listed, and ranked in a proposed
sequence of use. Thus, the markers within a
group may all be utilized at the same time or
utilized sequentially until one is positive. If all
are completed and none is positive, the recommendation is to move to the next set. One
deviation from the above ‘morphology before
immunophenotype’ proposal is the cautious,
provisional recognition that any morphology
with positive nuclear Oct 3/4, Sox 2, Nanog
or Sall4 would also represent a stem cell immunophenotype. The members also discussed and
agreed that any other antibodies one chose to
use in any of the above three categories are
optional, including, for example, K14 and c-kit
(CD117).
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natural histories of these different kinds of
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b(HB)-PLC differ from their single phenotype,
‘classic’ counterparts? Are stem cell features a
curiosity only relevant for understanding hepatocarcinogenesis or do they have true prognostic
and/or treatment implications?
●● Given the heterogeneity within b(HB)-PLC

what is sufficient tumor sampling? Is single needle core sampling of tumors with suspiciously
varied radiographic appearance sufficient? Or
do separate biopsy specimens need to be
obtained from areas with different radiologic
appearances?
●● What are the minimal criteria for including

immunostains for subclassification? Further,
what will be the role for the more sophisticated
molecular studies that are becoming increasingly
available?
●● Does treatment of pure HCC sometimes lead

to emergence of b(HB)-PLC or are recurrences
of b(HB)-PLC post-treatment of a classical
HCC evidence that it originally was, in fact, an
undiagnosed b(HB)-PLC, prior to treatment?
Or are both pathways for post-treatment tumor
appearance possible?
●● What is the post-treatment history of different

types of b(HB)-PLC?
The literature cited and observations described
in this review as well as the attempts to answer
questions such as those above will vastly extend
our knowledge of the biology of hepatocarcinogenesis. In terms of clinical practice, however, the
growing acceptance of b(HB)-PLC poses major
challenges to all professionals involved in the care
of patients with liver cancer: imaging and interventional radiology colleagues, clinical oncologists,
liver surgeons and transplant surgeons as the ‘natural history’ of this tumor phenotype is still being
actively studied. As demonstrated, these tumors
are certainly challenging for pathologists in terms
of histological diagnosis and nomenclature.
Future perspective
We are continuing and also at the beginning
of a fascinating journey for all those clinicians
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